The New Selective Estrogen Receptor Modulator MDL 103,323 Increases Bone Mineral Density and Bone Strength in Adult Ovariectomized Rats

1999 ◽  
Vol 10 (5) ◽  
pp. 369-376 ◽  
Author(s):  
P. Ammann ◽  
S. Bourrin ◽  
J.-P. Bonjour ◽  
F. Brunner ◽  
J.-M. Meyer ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Estrogen Receptor ◽  
Bone Strength ◽  
Bone Mineral ◽  
Selective Estrogen Receptor Modulator ◽  
Ovariectomized Rats ◽  
Mineral Density ◽  
Receptor Modulator

Influence of electro-acupuncture on bone mineral density, bone strength and ultrastructure in ovariectomized rats

Bone ◽  
2006 ◽  
Vol 38 (3) ◽  
pp. 27-28 ◽  
Author(s):  
Z.G. Luo ◽  
A.T. Wang ◽  
W.S. Yu ◽  
Y. Zhao ◽  
P. Hu ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Strength ◽  
Bone Mineral ◽  
Ovariectomized Rats ◽  
Mineral Density

scholarly journals Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta

2003 ◽  
pp. 351-362 ◽  
Author(s):  
D Seidlova-Wuttke ◽  
O Hesse ◽  
H Jarry ◽  
V Christoffel ◽  
B Spengler ◽  
...  
Keyword(s):  
Gene Expression ◽  
Estrogen Receptor ◽  
Selective Estrogen Receptor Modulator ◽  
Ovariectomized Rats ◽  
Tartrate Resistant Acid Phosphatase ◽  
Complement Protein ◽  
Cimicifuga Racemosa ◽  
Mineral Density ◽  
Receptor Modulator ◽  
Igf I

OBJECTIVE: Some phytoestrogens are believed to have selective estrogen receptor modulator (SERM) activity with no action in the uterus but beneficial effects in the hypothalamo/pituitary unit and in the bone and are presently the focus of clinical interest. In the present experiments, the effects of the clinically used Cimicifuga racemosa (CR) extract BNO 1055 in the uterus, in the bone and on serum luteinizing hormone (LH) were compared with the effects of estradiol-17beta (E(2)) under acute and chronic conditions in ovariectomized rats. METHODS: Ovariectomized rats were treated either acutely (6 h) or chronically (3 Months) with E(2) or the CR extract. Gene expression of some estrogen-regulated genes in the metaphysis of the tibia and the uterus was determined. Furthermore, bone mineral density was measured by quantitative computer tomography. RESULTS: When given acutely, both E(2) and the CR extract inhibited LH secretion and slightly stimulated gene expression of IGF-I, collagen-1alpha1, osteoprotegerin and osteocalcin (all osteoblast products), and of tartrate-resistant acid phosphatase (TRAP, an osteoclast product) in the metaphysis of the femur. While E(2) stimulated uterine weight and expression of progesterone receptor (PR), the complement protein (C3) and IGF-I genes, and inhibited gene expression of the estrogen receptor beta (ERbeta) in the uterus, no such effect was observed under acute CR treatment. After chronic application with pelleted food over 3 Months E(2) had profound effects in the uterus on weight and gene expression (ERbeta, PR, C3 and IGF-I) which were not seen in the CR-treated animals. Within 3 Months after ovariectomy, control rats had lost more than 50% of the metaphyseal bone mass of the tibia, an effect prevented by E(2) and partially by CR supplementation. CONCLUSIONS: These data confirm the concept that the CR extract BNO 1055 contains as yet unidentified substances with SERM properties which act in the hypothalamo/pituitary unit and in the bone but not in the uterus.

scholarly journals Growth and Bone Mineral Density Changes in Ovariectomized Rats Treated with Estrogen Receptor Alpha or Beta Agonists

2020 ◽  
Vol 35 (45) ◽  
Author(s):  
Byung Ho Kang ◽  
Ja Hyang Cho ◽  
So Youn Kim ◽  
Kyoung A Jeong ◽  
Shin-Hee Kim ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Estrogen Receptor ◽  
Bone Mineral ◽  
Estrogen Receptor Alpha ◽  
Ovariectomized Rats ◽  
Mineral Density ◽  
Receptor Alpha ◽  
Beta Agonists

Flaxseed Does not Antagonize the Effect of Ultra-Low-Dose Estrogen Therapy on Bone Mineral Density and Biomechanical Bone Strength in Ovariectomized Rats

2009 ◽  
Vol 72 (20) ◽  
pp. 1209-1216 ◽  
Author(s):  
Sandra M. Sacco ◽  
Jessica M. Y. Jiang ◽  
Sandra Reza-López ◽  
David W. L. Ma ◽  
Lilian U. Thompson ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Strength ◽  
Bone Mineral ◽  
Low Dose ◽  
Estrogen Therapy ◽  
Ovariectomized Rats ◽  
Mineral Density

Impaired Estrogen Sensitivity in Bone by Inhibiting Both Estrogen Receptor a and b Pathways*

2020 ◽  
Author(s):  
Lungwani Muungo
Keyword(s):  
Bone Mineral Density ◽  
Estrogen Receptor ◽  
Bone Loss ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Female Rats ◽  
Wild Type ◽  
Mineral Density ◽  
Transgenic Rats ◽  
Estrogen Sensitivity

Although it is well established that estrogen deficiencycauses osteoporosis among the postmenopausalwomen, the involvement of estrogen receptor (ER) in itspathogenesis still remains uncertain. In the presentstudy, we have generated rats harboring a dominantnegative ERa, which inhibits the actions of not only ERabut also recently identified ERb. Contrary to our expectation,the bone mineral density (BMD) of the resultingtransgenic female rats was maintained at the same levelwith that of the wild-type littermates when sham-operated.In addition, ovariectomy-induced bone loss wasobserved almost equally in both groups. Strikingly, however,the BMD of the transgenic female rats, after ovariectomized,remained decreased even if 17b-estradiol(E2) was administrated, whereas, in contrast, the decreaseof littermate BMD was completely prevented byE2. Moreover, bone histomorphometrical analysis ofovariectomized transgenic rats revealed that the higherrates of bone turnover still remained after treatmentwith E2. These results demonstrate that the preventionfrom the ovariectomy-induced bone loss by estrogen ismediated by ER pathways and that the maintenanceof BMD before ovariectomy might be compensatedby other mechanisms distinct from ERa and ERbpathways.

scholarly journals Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hyemin Jeong ◽  
In Young Kim ◽  
Eun-Kyung Bae ◽  
Chan Hong Jeon ◽  
Kwang-Sung Ahn ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Gut Microbiota ◽  
Small Animal ◽  
Joint Inflammation ◽  
Fecal Calprotectin ◽  
Selective Estrogen Receptor Modulator ◽  
Mineral Density ◽  
Receptor Modulator ◽  
Significant Difference ◽  
Microbiota Diversity

AbstractAnkylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM) lasofoxifene (Laso) on disease activity of SpA. Mice were randomized into zymosan-treated, zymosan + 17β-estradiol (E2)-treated, and zymosan + Laso-treated groups. Arthritis was assessed by 18F-fluorodeoxyglucose (18F-FDG) small-animal positron emission tomography/computed tomography and bone mineral density (BMD) was measured. Fecal samples were collected and 16S ribosomal RNA gene sequencing was used to determine gut microbiota differences. Both zymosan + E2-treated mice and zymosan + Laso-treated mice showed lower arthritis clinical scores and lower 18F-FDG uptake than zymosan-treated mice. BMD was significantly higher in zymosan + E2-treated mice and zymosan + Laso-treated mice than zymosan-treated mice, respectively. Fecal calprotectin levels were significantly elevated at 8 weeks after zymosan injection in zymosan-treated mice, but it was not significantly changed in zymosan + E2-treated mice and zymosan + Laso-treated mice. Gut microbiota diversity of zymosan-treated mice was significantly different from zymosan + E2-treated mice and zymosan + Laso-treated mice, respectively. There was no significant difference in gut microbiota diversity between zymosan + E2-treated mice and zymosan + Laso -treated mice. Laso inhibited joint inflammation and enhanced BMD in SKG mice, a model of SpA. Laso also affected the composition and biodiversity of gut microbiota. This study provides new knowledge regarding that selected SpA patients could benefit from SERM treatment.

Sign in / Sign up

Export Citation Format

Share Document